Iberfar and Herbolea Biotech announce a new GMP, solventless medical cannabis API: ≥90% total cannabinoids, >80% THC
Commercial availability expected from November 2026. Pre-bookings now open.
Lisbon / Florence, 13 February 2026 — Iberfar, the Portuguese company with more than 100 years of leadership in pharmaceutical manufacturing, which recently launched FAI Therapeutics, its business unit dedicated to medical Cannabis and Herbolea Biotech, the Italian leader in the development of solventless extraction technologies for botanicals with operating facilities in seven states, today announced a strategic collaboration to produce a new, high-purity ingredient for the medical cannabis sector.
The new ingredient is manufactured in a GMP environment and is specified at ≥90% total cannabinoids, with THC representing more than 80% of the cannabinoid content. According to the partners, it is the purest ingredient in its category produced without the use of chemical solvents, combining pharmaceutical-grade quality systems with the repeatability required for medical supply chains.
High-purity API with same-plant terpene fraction formulation options
In addition to its purity and potency profile, the extract can be formulated with a terpene fraction obtained from the same plant, enabling “same-plant” formulation options designed to support consistency, traceability, and product development needs in medical applications.
Timeline and availability
The ingredient will be available as an API (Active Pharmaceutical Ingredient) starting November 2026. Pre-bookings are now open, allowing qualified customers to reserve production slots and plan volumes in advance.
Strategic rationale
This particular partnership combines:
Iberfar’s industrial manufacturing capability and long-standing GMP culture and standards in pharmaceutical industry, and
Herbolea Biotech’s proprietary expertise in solventless botanical extraction at industrial scale across multiple operating jurisdictions.
Statements
“This collaboration is a concrete step toward industrializing next-generation medical cannabis ingredients with the stricter quality control and systems from advanced pharmaceutical industry in regulated markets and pharmaceutical supply chains,” said a spokesperson for Iberfar.
“We are bringing forward a solventless platform focused on maximizing purity and reproducibility, while enabling the option to integrate a terpene fraction sourced from the same plant,” added a spokesperson for Herbolea Biotech.
About Iberfar
Iberfar is the main company of a privately-owned Portuguese pharmaceutical group founded in 1924. With a century of experience, its core business is contract manufacturing for solid and non sterile liquid forms. The company takes pride in delivering top-quality products with short delivery times while offering the flexibility to meet the unique needs of each client. As a dedicated pharmaceutical contract manufacturer, it operates a state-of-the-art EU cGMP manufacturing site conveniently located near Lisbon, just 20 minutes from major logistic access points.
By leveraging the expertise and resources of Agrovete, Iberfar and Ferraz Lynce, the group has developed a fully verticalized, in-house business unit, FAI Therapeutics, dedicated exclusively to medical cannabis. This integrated approach ensures the highest quality and safety of all our products, from cultivation and extraction to production and distribution.
About Herbolea Biotech
Herbolea Biotech develops solventless technologies for botanical extraction and processing, with operating facilities in seven states and a focus on industrial scalability and process innovation.
Media Contacts
Iberfar Press Office
Email: geral@iberfar.pt
Herbolea Biotech Press Office
Email: info@herbolea.com
